Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA
PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...
Cardiovascular Risk
Advertisement
Amgen Shows Repatha Reduces Death Risk in High-Risk Patients
Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...
Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
Dimerix Licenses DMX-200 to Everest Medicines in Asia
MELBOURNE, Australia, June 16, 2026 Dimerix Limited has announced a landmark exclusive licensing agreement with Everest Medicines for the...
Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
Advertisements
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Apnimed Highlights Phase 3 AD109 OSA Data at ATS 2026
CAMBRIDGE, Mass., May 11, 2026 Apnimed announced multiple scientific presentations, including three oral presentations and a late-breaking poster, at...
FDA Approves LIB Therapeutics’ LEROCHOL™ for High LDL Cholesterol
WASHINGTON, D.C. — December 15, 2025 — LIB Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Baxdrostat Achieves Primary Endpoint in Phase III Trial for rHTN
SLondon, UK – October 7, 2025 – AstraZeneca announced that Baxdrostat met the primary endpoint in the Bax24 Phase...
Advertisement
